title: Treatment of therapy-resistant sarcoidosis with adalimumab.
abstract: A possible role of tumor necrosis factor alpha (TNFalpha) in the pathomechanism of sarcoidosis must be considered in the analysis of this disorder since elevated concentrations of this cytokine have been found. In addition, TNFalpha expression could be demonstrated in sarcoid granulomata [1]. It is well known that TNFalpha plays a crucial role in granulomatous inflammation, e.g., in mycobacterial diseases [2]. Therefore, TNFalpha blockade is a potential approach in the therapy for sarcoidosis. Up to now, various cases of therapy-resistant sarcoidosis treated with anti-TNFalpha (infliximab and etanercept) have been reported [3-8]. Here, we describe successful treatment using adalimumab, a human recombinant immunoglobulin (Ig) G1 anti-TNF monoclonal antibody [9].
authors.affiliation: Avenida Dr. Oloriz sn, 18006, Granada, Spain. JLCALLEJA@telefonica.net
authors.forename: José Luis
authors.initials: JL
authors.lastname: Callejas-Rubio
authors.forename: Norberto
authors.initials: N
authors.lastname: Ortego-Centeno
authors.forename: Lourdes
authors.initials: L
authors.lastname: Lopez-Perez
authors.forename: Maria Nicolas
authors.initials: MN
authors.lastname: Benticuaga
mesh_terms: D000068879:Adalimumab; D000328:Adult; D001741:Black or African American; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D004351:Drug Resistance; D006801:Humans; D008297:Male; D012507:Sarcoidosis / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab